Dejian Ma

Dr. Dejian Ma

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2021 in Recent Progress in Materials
Verified
Journal Article
Open access
PDF file
SKSydney Katras
Sydney Katras
DMDejian Ma
Dejian Ma
ADAyman Al Dayeh
Ayman Al Dayeh
DTDavid Tipton
David Tipton
Bisphenol A (BPA) is a widely used synthetic compound that has been identified as an endocrine disruptor. It has been linked to adverse health effects such as developmental defects, infertility in both men and women, cardiovascular disease, and obesity. There has been increased interest in BPA’s effects on the developing fetus and data has revealed that doses below the presumed safe dose can produce harmful effects. Orthodontic clear aligner therapy is a popular treatment modality that involves the patient wearing sets of plastic aligners up to 22 hours per day for the duration of treatment. The BPA release from these aligners was rarely investigated. The objective of this study was to detect, quantify, and compare the amount of BPA released by 3 popular brands of orthodontic aligners in artificial saliva, artificial gastric fluid, and ethanol. Equal amounts of SmileDirectClub®, Invisalign®, and Essix Ace® aligners were placed in sterile glass vials and submerged in 5.5mL artificial saliva, artificial gastric fluid, and ethanol. Samples were incubated at 37°C and 1 mL aliquots were removed at various time points. Samples were prepared and analyzed using high performance liquid chromatography tandem mass spectrometry. BPA was released from all three brands of aligners with great variability. Peak BPA concentrations were detected in artificial saliva; Smile Direct Club® produced 5.0 ng/mL after 20 days, Invisalign® released 3.5ng/mL after 24 hours, and Essix Ace® released 6.3ng/mL after 10 days of incubation in artificial saliva. There was no significant difference in BPA concentration between the 3 types of aligners in the 3 media. When comparing time points, there was a significant increase of BPA release in the first 24 hours after incubation compared to the baseline (p<0.001). There is potential BPA release from orthodontic aligners. There was no significant difference in the amount of BPA released between the three types of aligners at any time point. The majority of BPA release occurred during the first 24 hours.

17 September 2015 in Molecules
Verified
Journal Article
Open access
PDF file
SBSouvik Banerjee
Souvik Banerjee
JWJin Wang
Jin Wang
SPSusan Pfeffer
Susan Pfeffer
DMDejian Ma
Dejian Ma
Lawrence PfefferLawrence Pfeffer
Lawrence Pfeffer
DMDuane Miller
Duane Miller
A novel series of 5H-chromenopyridines was identified as anticancer agents in our continuing effort to discover and develop new small molecule anti-proliferative agents. Based on our initial lead SP-6-27 compound, we designed and synthesized novel tricyclic 5H-thiochromenopyridine and 5H-chromenopyridine analogs to evaluate the impact of an additional ring, as well as conformational flexibility on cytotoxic activity against human melanoma and glioma cell lines. All of the 5H-thiochromenopyridines have been achieved in good yields (89%–93%) using a single-step, three-component cyclization without the need for purification. The 5H-chromenopyridine analog of the potent 5H-thiochromenopyride was obtained in a good yield upon purification. All newly-prepared 5H-thiochromenopyridines showed good to moderate cytotoxicity against three melanoma and two glioma cell lines (3–15 μM). However, the 5H-chromenopyridine analogue that we prepared in our laboratory lost cytotoxic activity. The moderate cytotoxic activity of 5H-thiochromenopyridines shows the promise of developing chromenopyridines as potential anticancer agents.

1 July 2019 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
KAKinsie E. Arnst
Kinsie E. Arnst
YWYuxi Wang
Yuxi Wang
ZLZining Lei
Zining Lei
DHDong-jin Hwang
Dong-jin Hwang
GKGyanendra Kumar
Gyanendra Kumar
Wei LiWei Li
Wei Li
Interfering with microtubule dynamics is a well-established strategy in cancer treatment; however, many microtubule-targeting agents are associated with drug resistance and adverse effects. Substantial evidence points to ATP-binding cassette (ABC) transporters as critical players in the development of resistance. Herein, we demonstrate the efficacy of DJ95 (2-(1H-indol-6-yl)-4-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-c]pyridine), a novel tubulin inhibitor, in a variety of cancer cell lines, including malignant melanomas, drug-selected resistant cell lines, specific ABC transporter–overexpressing cell lines, and the National Cancer Institute 60 cell line panel. DJ95 treatment inhibited cancer cell migration, caused morphologic changes to the microtubule network foundation, and severely disrupted mitotic spindle formation of mitotic cells. The high-resolution crystal structure of DJ95 in complex with tubulin protein and the detailed molecular interactions confirmed its direct binding to the colchicine site. In vitro pharmacological screening of DJ95 using SafetyScreen44 (Eurofins Cerep-Panlabs) revealed no significant off-target interactions, and pharmacokinetic analysis showed that DJ95 was maintained at therapeutically relevant plasma concentrations for up to 24 hours in mice. In an A375 xenograft model in nude mice, DJ95 inhibited tumor growth and disrupted tumor vasculature in xenograft tumors. These results demonstrate that DJ95 is potent against a variety of cell lines, demonstrated greater potency to ABC transporter–overexpressing cell lines than existing tubulin inhibitors, directly targets the colchicine binding domain, exhibits significant antitumor efficacy, and demonstrates vascular-disrupting properties. Collectively, these data suggest that DJ95 has great potential as a cancer therapeutic, particularly for multidrug resistance phenotypes, and warrants further development. Significance Statement Paclitaxel is a widely used tubulin inhibitor for cancer therapy, but its clinical efficacy is often limited by the development of multidrug resistance. In this study, we reported the preclinical characterization of a new tubulin inhibitor DJ95, and demonstrated its abilities to overcome paclitaxel resistance, disrupt tumor vasculature, and exhibit significant antitumor efficacy.

1 July 1999 in Tetrahedron
Verified
Journal Article
Closed access
KLKe-Qing Ling
Ke-Qing Ling
JYJia-Hai Ye
Jia-Hai Ye
XCXian-Yang Chen
Xian-Yang Chen
DMDejian Ma
Dejian Ma
Jianhua XuJianhua Xu
Jianhua Xu

2 May 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SDShanshan Deng
Shanshan Deng
RKRaisa I. Krutilina
Raisa I. Krutilina
KHKelli L. Hartman
Kelli L. Hartman
HCHao Chen
Hao Chen
DPDeanna Parke
Deanna Parke
Wei LiWei Li
Wei Li
Triple-negative breast cancer (TNBC) is a highly aggressive type of breast cancer. Unlike other subtypes of breast cancer, TNBC lacks hormone and growth factor receptor targets. Colchicine-binding site inhibitors (CBSI) targeting tubulin have been recognized as attractive agents for cancer therapy, but there are no CBSI drugs currently FDA approved. CH-2-77 has been reported to have potent antiproliferative activity against a panel of cancer cells in vitro and efficacious antitumor effects on melanoma xenografts, yet, its anticancer activity specifically against TNBC is unknown. Herein, we demonstrate that CH-2-77 inhibits the proliferation of both paclitaxel-sensitive and paclitaxel-resistant TNBC cells with an average IC50 of 3 nmol/L. CH-2-77 also efficiently disrupts the microtubule assembly, inhibits the migration and invasion of TNBC cells, and induces G2–M cell-cycle arrest. The increased number of apoptotic cells and the pattern of expression of apoptosis-related proteins in treated MDA-MB-231 cells suggest that CH-2-77 induces cell apoptosis through the intrinsic apoptotic pathway. In vivo, CH-2-77 shows acceptable overall pharmacokinetics and strongly suppresses the growth of orthotopic MDA-MB-231 xenografts without gross cumulative toxicities when administered 5 times a week. The in vivo efficacy of CH-2-77 (20 mg/kg) is comparable with that of CA4P (28 mg/kg), a CBSI that went through clinical trials. Importantly, CH-2-77 prevents lung metastasis originating from the mammary fat pad in a dose-dependent manner. Our data demonstrate that CH-2-77 is a promising new generation of tubulin inhibitors that inhibit the growth and metastasis of TNBC, and it is worthy of further development as an anticancer agent.

Verified
Journal Article
Open access
PDF file
FTFaiza Tahia
Faiza Tahia
DMDejian Ma
Dejian Ma
DSDaniel J. Stephenson
Daniel J. Stephenson
SBSandip K Basu
Sandip K Basu
NMNobel A. Del Mar
Nobel A. Del Mar
Nawajes MandalNawajes Mandal
Nawajes Mandal
Retinal degenerative diseases lead to irreversible vision loss due to photoreceptor cell death, driven by complex genetic and environmental factors. Ceramide, a sphingolipid metabolite, emerges as a critical mediator in the apoptotic cascade associated with retinal degeneration. Our previous work demonstrated L-Cycloserine’s ability to protect photoreceptor-derived cells from oxidative stress by inhibiting the de novo ceramide pathway and thus prompting further investigation on its effect in the in vivo retina. This study investigates the potential of L-Cycloserine to protect albino BALB/c mice against light-induced retinal degeneration (LIRD). L-Cycloserine, in an optimal dose, administered systemically 30 min before LIRD, was found to prevent photoreceptor cell death significantly from light-induced degeneration. We further determined the retinal bioavailability and pharmacokinetic behavior of L-Cycloserine, its effect on sphingolipid profile, expression of sphingolipid biosynthetic, and cell death-promoting genes and proteins from the retina to understand the underlying mechanisms. This study lays the groundwork for further preclinical and clinical investigations into L-Cycloserine’s potential as a novel therapeutic in treating retinal degenerative diseases.